Novo Nordisk INC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$186Mgeneral payments (2019-2025)
$400Kresearch payments (2019-2025)
246,549clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Ozempic $30M associated (2023-2025)
- Wegovy $24M associated (2023-2025)
- Rybelsus $15M associated (2023-2025)
- Sogroya $1.1M associated (2023-2025)
- Saxenda $401K associated (2023-2025)
- Alhemo $342K associated (2023-2025)
- Victoza $335K associated (2023-2025)
- Novoseven $273K associated (2023-2025)
- Rivfloza $259K associated (2023-2025)
- Esperoct $175K associated (2023-2025)
- Rebinyn $139K associated (2023-2025)
- Norditropin $109K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Joshua Stolker | Washington, MO | Interventional Cardiology | $566,899.40 |
| Robert Busch | Albany, NY | Endocrinology, Diabetes & Metabolism | $536,193.36 |
| Aaron King | San Antonio, TX | Family Medicine | $527,952.07 |
| Lee Kaplan | Lebanon, NH | Gastroenterology (Internal Medicine) | $523,775.14 |
| Carlos Campos | New Braunfels, TX | Family Medicine | $521,578.04 |
| Pablo Mora | Dallas, TX | Endocrinology, Diabetes & Metabolism | $493,880.66 |
| Michael Kaplan | Smithtown, NY | Internal Medicine | $487,247.67 |
| Leigh Perreault | Boulder, CO | Endocrinology, Diabetes & Metabolism | $483,498.07 |
| Ken Fujioka | San Diego, CA | Endocrinology, Diabetes & Metabolism | $469,533.77 |
| Deborah Horn | Bellaire, TX | Adult Medicine | $467,646.55 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.